Last reviewed · How we verify
Formulation C: OnabotulinumtoxinA
OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction. Used for Blepharospasm, Cervical dystonia, Spasticity.
At a glance
| Generic name | Formulation C: OnabotulinumtoxinA |
|---|---|
| Also known as | BOTOX |
| Sponsor | Allergan |
| Drug class | Botulinum toxin |
| Target | Acetylcholine release |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By blocking acetylcholine release, onabotulinumtoxinA reduces muscle spasms and contractions, providing relief for conditions such as blepharospasm and cervical dystonia. This mechanism is achieved through the inhibition of acetylcholine release at the neuromuscular junction.
Approved indications
- Blepharospasm
- Cervical dystonia
- Spasticity
- Hemifacial spasm
- Strabismus
- Axillary hyperhidrosis
- Severe primary axillary hyperhidrosis
- Lateral ptosis
- Severe glabellar lines
- Upper limb spasticity
Common side effects
- Eyelid ptosis
- Diplopia
- Headache
- Facial asymmetry
- Dry mouth
- Nausea
- Injection site pain
- Injection site erythema
- Injection site induration
- Injection site pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formulation C: OnabotulinumtoxinA CI brief — competitive landscape report
- Formulation C: OnabotulinumtoxinA updates RSS · CI watch RSS
- Allergan portfolio CI